Purpose: Insulin resistance is a key feature of the metabolic syndrome and type 2 diabetes, in which noninvasive assessment is not currently allowed by any methodology. We previously validated an iodinated tracer of glucose transport (6DIG) and a new methodology for the in vivo quantification of cardiac insulin resistance in rodents. The aim of this study was to investigate the safety, biodistribution, and radiation dosimetry of this method using 123 I-6DIG in 5 healthy and 6 diabetic volunteers. Methods: The collection of adverse effects (AEs) and medical supervision of vital parameters and biological variables allowed the safety evaluation. Biodistribution was studied by sequentially acquiring whole-body images at 1, 2, 4, 8, and 24 hours postinjection. The total number of disintegrations in each organ normalized to the injected activity was calculated as the area under the time-activity curves. Dosimetry calculations were performed using OLINDA/EXM. Results: No major adverse events were observed. The average dose corresponding to the 2 injections of 123 I-6DIG used in the protocol was 182.1 ± 7.5 MBq. A fast blood clearance of 123 I-6DIG was observed. The main route of elimination was urinary, with greater than 50% of urine activity over 24 hours. No blood or urine metabolite was detected.
I
nsulin resistance (IR) as partially characterized by a defect in insulinstimulated glucose transport in insulin-sensitive tissues is a key feature of the metabolic syndrome, which also involves obesity, hypertension, an impairment in carbohydrate metabolism, and dyslipidemia with elevated triglyceridemia and decreased high-density lipoproteins (HDLs) levels. [1] [2] [3] The presence of the metabolic syndrome is strongly associated with an increased occurrence of coronary artery disease and heart failure in type 2 diabetes (T2D) patients as well as nondiabetic individuals. The public health challenge represented by the metabolic syndrome is best exemplified by its elevated prevalence (15%-25%) in Western countries. 4 However, the routine clinical assessment of IR is currently not allowed by any methodology with the euglycemic hyperinsulinemic clamp technique remaining the criterion standard with the widely acknowledged limitations of complexity and duration precluding its clinical routine use. 5 Simpler indexes based on fasting glycemia and insulinemia such as the homeostasis model assessment (HOMA) or the quantitative insulin sensitivity check index (QUICKI) have been proposed but lack accuracy and informativeness. [6] [7] [8] Furthermore, such indexes are limited to global IR and do not provide any tissue-specific IR data. 18 F-FDG or 11 C-3-O-methyl-D-glucose (3-OMG) and PET imaging have been proposed for the regional assessment of IR with limitations similar to those described previously since the methodology still requires to perform an euglycemic hyperinsulinemic clamp as well. 9, 10 We previously validated the 6-deoxy-6-iodo-D-glucose (6DIG) as an iodinated tracer of glucose transport with a biological behavior similar to that of 3-OMG. 11, 12 We demonstrated the in vivo feasibility of IR assessment with 123/125 I-6DIG in mice and rats 13, 14 and then developed an experimental protocol allowing the assessment of cardiac IR in rats without the need for an euglycemic hyperinsulinemic clamp. 15 The aim of the present study was to evaluate the safety, biodistribution, and dosimetry of the 123 I-6DIG injection in healthy and diabetic volunteers to proceed with the clinical translation of the methodology previously validated preclinically.
PATIENTS AND METHODS

Radiopharmaceutical Preparation
Iodine was purchased from IBA/CIS Bio International ( 123 NaI for labeling of radiopharmaceuticals as carrier-free iodine in alkaline solution; 3700 MBq/mL). 6DIG and NaI (4 μg/mL, acetone solution) were obtained as active pharmaceutical ingredients from ERAS Labo (Saint-Nazaire-les-Eymes, France). Sterile saline (NaCl 0.9%) and water for injection were purchased from B. Braun Medical. Methanol and acetonitrile for quality controls were of analytical grade and were obtained from Carlo Erba. Radioiodinated 6DIG was prepared through an isotopic exchange method as previously described 14 and modified for clinical use as follows: radiopharmaceutical was prepared by hospital radiopharmacy in a grade A hot cell placed in a grade C environment. All vials were provided with a lead shield for radiation protection. 6DIG (5 mg) was dissolved in 1 mL solution NaI/acetone and added to 123 NaI (259 MBq, 70 μL).
The solution was heated to 95°C for 1 hour. After cooling to room temperature, acetone was removed by evaporation at 80°C for 10 minutes and then an additional 15 minutes after adding 100 μL of sterile water. The residue was dissolved in 1 mL of sterile water, and the reaction solution was purified by anion exchange chromatography (cartridge OASIS Max Waters) using 0.9% NaCl as eluent to remove free 123 I. The volume was adjusted to 8 mL with 0.9% NaCl. Subsequently, the solution was transferred through 2 sterile filters (0.2 μm, Sartorius) into a sealed glass vial.
Quality Controls
A small aliquot of the final product was used for quality controls: appearance of the solution, pH, identity of radionuclide and of radiolabeled compound, radionuclide and radiochemical purity, level of chemical impurities, residual solvents, specific activity, bacterial endotoxins, and sterility. Analyses were performed according to European Pharmacopoeia. The identification of the product as well as chemical and radiochemical purity were determined by high-performance liquid chromatography (HPLC) with ultraviolet detection. The column used was a C18 spherisorb 4.6 Â 150-mm column (Waters). The mobile phase was pure water, the flow was 1 mL/min, and ultraviolet detection was performed at λ = 254 nm. The radiochemical purity was also determined by high-performance thin layer chromatography on aluminum thin-layer chromatography plates, coated with silicagel 60 (F254, Merck) that was developed with acetonitrile/methanol 95/5 vol/vol. Tryptone Soya Broth and Thioglycollate broth with resazurin (Biomérieux) were used to confirm the absence of bacterial growth. The level of residual acetone was determined by gas chromatography. Tests on bacterial endotoxins, sterility, and residual acetone were performed after product utilization.
Study Population
The study was approved by the institutional review board, local ethics committee, and all volunteers signed an informed consent form after receiving a thorough explanation of the study by a qualified physician. The clinical trial registration number of this study was NCT01493934. Before participating, each volunteer had medical and laboratory examinations to verify inclusion criteria. Initially 12 patients (age range, 35-60 years) consisting of 6 healthy volunteers (3 nonlactating women using contraception or postmenopausal and 3 men) and 6 patients with T2D (1 nonlactating woman using contraception and 5 men) were included in this study. The inclusion criteria for healthy volunteers were as follows: 20 kg/m 2 < body mass index < 25 kg/m 2 , waist circumference <94 cm for male and <80 cm for woman, fasting blood glucose between 3.8 and 5.8 mmo/L, fasting insulin level between 3 and 13 μIU/mL, glycated hemoglobin (HbA1c) <6%, total cholesterol <2 g/L, low-density lipoproteins <1.6 g/L, HDLs >0.4 g/L for male and >0.5 g/L for woman, and triglycerides level <1.5 g/L. The inclusion criteria for diabetic volunteers were as follows: stable T2D with no ketoacidosis sign during the last month, HbA1c between 6% and 8%, treated only with metformin or diet. All volunteers with a history of myocardial infarction, acknowledged coronary artery disease, heart rhythm disorders, severe hypertension, stroke, epilepsy, pituitary surgery, disease likely to reduce the ability of absorption, diffusion and elimination of 123 I-6DIG, treatment that could interfere with glucose metabolism, or other chronic disease were excluded.
The first healthy volunteer was excluded from the study after the first 123 I-6DIG injection because of a high thyroid 123 I retention, which led to the subsequent thyroid saturation using potassium iodide before radiotracer injection in all volunteers (amendment accepted).
Protocol Design and Imaging Acquisition
Any treatment was stopped at least 48 hours before the 123 I-6DIG study. A potassium iodide tablet (130 mg) was then given to all the remaining volunteers (n = 11) the evening before the study, and another tablet was provided 12 to 24 hours later. After an 8-hour fast, a cannula was placed in the arm of each subject, and~92.5 MBq of 123 I-6DIG was administered intravenously as a bolus. Dynamic images were obtained (2-second image) during 15 minutes using a γ-camera (Infinia; GE Healthcare) with parallelhole, low-energy, and high-resolution collimator (H2505TJ, GE) and a 128 Â 128 matrix to study glucose transport under basal/fasting conditions. Insulin was then administered in accordance with the criterion standard, routine clinical procedure for dynamic stimulation of the hypothalamic-pituitary-adrenal axis (Actrapid; 0.1 IU/kg for healthy volunteers, 0.15-0.20 IU/kg for diabetic volunteers). 16 Five minutes after the insulin bolus, 123 I-6DIG injection and image acquisition were performed again as described previously to study insulin-stimulated glucose transport. Static whole-body images (12 cm/min, 1024 Â 512 matrix) were then obtained at 1, 2, 4, 8, and 24 hours after the first 6DIG injection to determine the biodistribution of the tracer over time. Intraindividual reproducibility was assessed by submitting 2 healthy volunteers to an additional injection of 123 I-6DIG (~92.5 MBq) in the basal/fasting state without insulin injection 14 days after the completion of the protocol.
Carbohydrate-rich juice or food was systematically proposed 15 minutes after insulin injection, or over the course of image acquisition to prevent severe hypoglycemia.
Safety Clinical Follow-up
A full clinical examination including blood pressure, heart rate measurements, and electrocardiogram was performed at the inclusion visit as well as 24 hours and 7 days after completion of the 6DIG protocol. Volunteers stayed under strict medical supervision during the whole hour after insulin injection to detect any clinical symptom of hypoglycemia.
Adverse effects (AEs) were monitored at each step of the study and collected using the volunteers' account before being graded according to the Medical Dictionary for Regulatory Activities System Organ Class.
Biologic Follow-up
A cannula was inserted intravenously in the arm not used for 123 I-6DIG injection. Blood samples were obtained upon the day of inclusion as well as 5 minutes before the injection and 24 hours and 7 days after. Electrolytes, complete blood cell count, platelet counts, prothrombin and activated partial thromboplastin time, glycemia, insulinemia, HbA1c, cholesterol, HDLs, low-density lipoproteins, triglycerides, aspartate transaminase, alanine transaminase, creatine phosphokinase, lactate dehydrogenase, alkaline phosphatase, bilirubin, gamma GT, urea, and creatinine were assayed. A pregnancy test was performed in women before 123 I-6DIG injection and during the last visit. Special attention was paid to the follow-up of the insulin test with serial blood glucose and insulin measurements at 0.5, 1, 2, 5, 10, 15, 20, 25, 30, 45, 60, and 75 minutes, and 24 hours.
Pharmacokinetics and Metabolites Radioactivity in Blood and Metabolites
Venous blood sapling was performed at 0.5, 1, 2, 5, 10, 15, 20, 25, 30, and 45 minutes, and 1, 4, 8, and 24 hours postinjection (PI) to evaluate blood well-counter (COBRA-5003, Packard) after centrifugation. Results were expressed as a percentage of the injected activity (%IA) after correction for 123 I decay. Plasma samples were also analyzed by radio-HPLC for the detection of potential metabolites.
Radioactivity in Urine and Metabolites
Urinary 123 I-6DIG activity was assessed using samples collected between 0-2, 2-4, 4-8, and 8-24 hours after injection and radioactivity assessment as described previously. Results were expressed as a %IA after correction for 123 I decay. Urine samples were also analyzed by radio-HPLC.
Radioactivity in the Feces
Feces were collected for 24 hours, and radioactivity was counted using a gamma-counter ARIES.
Biodistribution and Dosimetry
Regions of interest (ROIs) were manually placed on organs presenting a visible uptake of 123 I-6DIG, on whole-body images, in an anterior and posterior incidence face, to generate time-activity curves for each organ for 24 hours. The first image acquisition was performed before the first micturition so that the total whole-body activity computed from image analysis corresponded to the IA.
123
I-6DIG time-activity evolution for each organ was expressed as %IA after correction for 123 I decay. The estimation of radiation doses for the organs and the whole-body effective dose were obtained using OLINDA/EXM software (Vanderbilt University, Nashville, TN). Regions of interest were manually placed on the following organs: heart, lungs, thyroid, salivary glands, brain, liver, bladder, kidney, spleen, muscle, gonads, intestine, and stomach. Geometric means for each pair of decay and attenuation corrected conjugate ROIs were calculated by multiplying the net anterior counts by the net posterior counts and taking the square root of the product. Decay correction was necessary to compare each time point to the original whole-body activity level. The fraction of IA at each time point was then estimated by dividing the corrected geometric mean number of counts in each ROI by the net geometric mean number of counts in the initial whole-body image. The total number of disintegrations in each organ normalized to IA, subsequently referred to as the residence time (RT); kBq·h·kBq −1 was calculated as follows: RT = (AUC Â V organ )/IA; where AUC is the area under the curve of the non-decay-corrected time-activity curve, and V organ is the tabulated organ volume as used in OLINDA/ EXM. 17 The internal radiation dosimetry was evaluated through the RTs for the visible organs in each subject provided as an input to OLINDA/EXM. Absorbed doses were then estimated for each subject using the standardized adult male or female models in OLINDA/EXM, and effective doses were based on the tissue weighting factors from ICRP 60. 18 
Statistical Analysis
All results were presented as mean ± standard deviation (SD). For the 2 groups of volunteers, AE's frequency was expressed as number and the corresponding percentage, and statistical comparison was performed using Fisher exact test. Fisher F test was used for variances comparisons. Student t test and Mann-Whitney U test were used for paired/unpaired datasets with equal variances and unpaired datasets with unequal variances, respectively. Differences were considered significant for P < 0.05.
RESULTS
I-6DIG Preparation
The radiochemical purity after radiolabeling was 97.4% ± 1.6%. Unbound 123 I always represented less than 5% in each injected solution. Typical 123 I-6DIG HPLC profiles are displayed in Figure 1A .
Volunteers Characteristics
The main differences between the 2 groups of volunteers at the time of inclusion are presented in Table 1 . As expected, fasting glucose, insulin, HbA1c levels, and HOMA indexes were significantly higher in diabetic than in healthy volunteers while QUICKI indexes were significantly lower.
Safety
The injection of 123 I-6DIG was well tolerated with no significant modification of vital signs, clinical examination, or electrocardiogram. All recorded AEs are shown in Table 2 . Ten of the 11 volunteers reported at least 1 slight and transient AE. However, no severe AEs were recorded. In total, 19 AEs were notified including headache, somnolence (36.8%), or discomfort associated with venous catheters including injection site hemorrhage or hematoma Data represent mean ± SD (min-max). Comparison between healthy (n = 5) and diabetic (n = 6) volunteers: *P < 0.05, †P < 0.01. Comparison between t1 and t2: nonsignificant for both groups.
ND indicates not determined. (26.3%; Table 2 ). The number of subjects reporting at least 1 AE was comparable between the 2 groups of volunteers (P = 0.999).
Pharmacokinetics, Clearance, and Metabolites Plasma
As previously observed in rodents, 12,13 plasma clearance and blood clearance were superimposable (data not shown). Circulating 123 I-6DIG activity increased twice during the complete protocol after each bolus-injection before quickly decreasing ( Fig. 2A) .
123
I-6DIG blood clearance was fast with only 5.7 ± 2.2 %IA remaining 5 minutes after the first injection.
I-6DIG blood clearance was also evaluated on the second part of the protocol after insulin stimulation, between 25 minutes and 24 hours (Fig. 2B) . The data were best fitted with a double exponential curve giving a blood circulating half-life of 123 I-6DIG estimated approximately 7 minutes for the fast part of the curve and a blood circulating half-life approximately 8 hours for the slow part of the curve. No 123 I-6DIG metabolite was observed in any subjects throughout the study (Fig. 1B) (Fig. 3) . No 123 I-6DIG metabolite was observed during the 24-hour follow-up.
I-6DIG represented 64.6% ± 8.0% of the radioactive profile between 0 and 2 hours, 54.6% ± 18.4% between 2 and 4 hours, and nearly 0% afterward due to the increasing corresponding presence of free I-6DIG was mainly detectable in organs involved in glucose metabolism such as the liver or in its elimination such as the kidneys and bladder (Figs. 4, 5) . activity decreased over time in these organs. Thyroid and stomach activity were observed, which could be attributed to the biodistribution of free 123 I (Figs. 4, 5) . A modest cardiac activity of 123 I-6DIG was observed (1.8 ± 1.4 %IA at 1 hour PI).
Dosimetry
The mean RTs for healthy and diabetic volunteers are summarized in Table 3 . The organs receiving the highest absorbed dose were the thyroid, stomach wall, urinary bladder wall, and osteogenic cells (Tables 3, 4 ). The total effective dose was slightly significantly higher in women than in men, 2.01·10 −2 ± 2.41·10 −3 mSv/MBq versus 1.65·10 −2 ± 2.63·10 −3 mSv/MBq, respectively (P < 0.05). No difference was observed between the total effective dose in healthy and diabetic volunteers (1.97·10 −2 ± 3.10·10 −3 mSv/MBq vs FIGURE 5. Time-activity curves from the major organs observable on nuclear images over a 24-hour period after 123 I-6DIG injection. Mean ± SD (error bars are shown both side for kidneys and 1-sided for clarity for the others). 1.69·10 −2 ± 2.79·10 −3 mSv/MBq, respectively, P = 0.12). No intraindividual difference was observed.
The total effective dose resulting from the evaluation of all volunteers was 1.81·10 −2 ± 0.31·10 −2 mSv/MBq, corresponding to an effective whole-body absorbed dose of 3.35 ± 0.57 mSv for a total IA of~185 MBq (Table 5) .
DISCUSSION
The main objective of this study was to evaluate the safety of 123 I-6DIG injection in humans. The administration of 123 I-6DIG was well tolerated with no major AE being recorded. Minor inconveniences were reported, with some appearing to be independent of 123 I-6DIG administration such as bruise at the point of draining, urinary infection, and urinary incontinence. In addition, the causal link between additional AE, such as nausea and headache, and I-6DIG activity was found in organs of elimination such as the stomach, bladder, and liver. Cardiac uptake was low with less than 2%IA at 1 hour PI. Previous in vitro or in vivo studies in rodents indicated that the cellular uptake of 6DIG through glucose transporters was fast. 11, 12, 14, 15 In addition, 123 I-6DIG may leave the cell through glucose transporters as well since it is not metabolized. The net flux of tracer will therefore depend on its concentration gradient between the blood and tissue compartments in vivo, with a concentration equilibrium being reached quickly after injection. Such in vivo kinetics account for the lack of 123 I-6DIG-specific organ retention.
As previously observed in animals,
123
I-6DIG excretion mainly occurred through the urinary tract with~60% of the injected activity being eliminated at 24 hours after injection. A weak yet significant thyroid retention was observed due to the presence of a low circulating fraction of free 123 I in the injected solution (2.66% ± 1.59%), which increased upon injection due to additional in vivo deiodination. Thyroid saturation using potassium iodide was therefore performed as usually done when using iodinated radiotracers.
The whole-body effective dose~3.35 mSv reached after completion of the 2 tracer injections was comparable to that observed for previously described routine clinical procedures.
CONCLUSIONS
The tracer of glucose transport 3.35 ± 0.57
Data are mean ± SD. n = 13: 7 males, 6 females.
